Edition:
United States

Infinity Pharmaceuticals Inc (INFI.OQ)

INFI.OQ on NASDAQ Stock Exchange Global Select Market

2.24USD
20 Apr 2018
Change (% chg)

$0.04 (+1.82%)
Prev Close
$2.20
Open
$2.24
Day's High
$2.24
Day's Low
$2.16
Volume
44,376
Avg. Vol
160,671
52-wk High
$3.75
52-wk Low
$0.93

Chart for

About

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145,... (more)

Overall

Beta: 2.55
Market Cap(Mil.): $116.39
Shares Outstanding(Mil.): 51.96
Dividend: --
Yield (%): --

Financials

  INFI.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -0.83 -- --
ROI: -55.94 -0.74 13.19
ROE: -64.26 -2.80 15.00

BRIEF-BVF Partners Reports 21.7 Pct Stake In Infinity Pharmaceuticals As Of April 10

* BVF PARTNERS LP REPORTS 21.7 PCT STAKE IN INFINITY PHARMACEUTICALS INC AS OF APRIL 10 - SEC FILING

Apr 12 2018

BRIEF-Infinity Pharma Qtrly Diluted Loss Per Common Share $0.14​

* INFINITY PHARMACEUTICALS PROVIDES COMPANY UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 15 2018

BRIEF-Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln​

* INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS NET LOSS FOR 2018 TO RANGE FROM $40 MILLION TO $50 MILLION​

Jan 08 2018

BRIEF-Infinity Q3 loss per share $0.14

* Infinity provides company update and reports third quarter 2017 financial results

Nov 07 2017

Earnings vs. Estimates